Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Gross Margin (2021 - 2025)

Apellis Pharmaceuticals has reported Gross Margin over the past 5 years, most recently at 85.13% for Q4 2025.

  • Quarterly results put Gross Margin at 85.13% for Q4 2025, up 436.0% from a year ago — trailing twelve months through Dec 2025 was 89.81% (up 488.0% YoY), and the annual figure for FY2025 was 89.81%, up 488.0%.
  • Gross Margin for Q4 2025 was 85.13% at Apellis Pharmaceuticals, down from 94.65% in the prior quarter.
  • Over the last five years, Gross Margin for APLS hit a ceiling of 99.92% in Q4 2021 and a floor of 79.4% in Q1 2025.
  • Median Gross Margin over the past 5 years was 88.35% (2024), compared with a mean of 88.93%.
  • Biggest five-year swings in Gross Margin: crashed -1404bps in 2023 and later skyrocketed 1170bps in 2025.
  • Apellis Pharmaceuticals' Gross Margin stood at 99.92% in 2021, then dropped by -13bps to 87.09% in 2022, then fell by -1bps to 86.4% in 2023, then dropped by -7bps to 80.78% in 2024, then rose by 5bps to 85.13% in 2025.
  • The last three reported values for Gross Margin were 85.13% (Q4 2025), 94.65% (Q3 2025), and 92.37% (Q2 2025) per Business Quant data.